Safety and Efficacy of Rechallenge With Immune Checkpoint Inhibitors in Advanced Solid Tumor: A Systematic Review and Meta‐Analysis

医学 科克伦图书馆 内科学 不利影响 入射(几何) 荟萃分析 系统回顾 肿瘤科 肺癌 梅德林 物理 政治学 法学 光学
作者
Huijun Xu,Yang Yang,Ying Yan,Mengge Li,Shusheng Wu,Lulu Cao,Wenju Chen,Huiqin Luo,Yifu He
出处
期刊:Cancer Medicine [Wiley]
卷期号:13 (20)
标识
DOI:10.1002/cam4.70324
摘要

ABSTRACT Background Immune checkpoint inhibitors (ICIs) have drastically shifted the current landscape toward a wide variety of malignancies. However, ICIs are interrupted owing immune‐related adverse events (irAEs), therapy completion, and disease progression. The risk–benefit of rechallenged ICIs remains inconclusive. Herein, a systematic review and meta‐analysis were conducted to evaluate the safety and efficacy of ICI rechallenge in the treatment of advanced solid tumor. Methods PubMed, Web of Science, Embase, and Cochrane Library were searched to analyze the efficacy and safety of ICI rechallenge. The study protocol was approved by the PROSPERO International Register of Systematic Reviews (CRD42022372222). The last updated search date was March 2, 2024. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), and incidence rates of all‐ and high‐grade irAEs were evaluated. Results A total of 41 retrospective studies comprising 2343 patients were ultimately enrolled for qualitative and quantitative assessments. A total of 1200 (51.2%) individuals were male and the median age was 66 years (range 18–97 years). The majority of the tumors was lung cancer ( n = 898, 38.3%). The occurrence rates of all‐grade and high‐grade (grade 3 or 4) irAEs between initial and readministration ICIs were not significantly different (all‐grade: OR, 0.75, 95% CI: 0.39–1.45, p = 0.40; I 2 = 87%; high‐grade: OR, 0.96, 95% CI: 0.62–1.49, p = 0.87, I 2 = 65%). ICIs restart presented a decreased ORR and DCR compared to initial ICI administration (ORR: OR, 0.36, 95% CI: 0.23–0.56, p < 0.00001; I 2 = 67%; DCR: OR, 0.62, 95% CI: 0.43–0.89, p = 0.010; I 2 = 53%). Seven studies with 513 patients for survival analysis revealed a nonsignificant difference in OS between the ICIs rechallenge and discontinuation cohorts (hazard ratio [HR]: 0.68, 95% confidence interval (CI): 0.35 to 1.35, p = 0.27). Conclusion Rechallenging immunotherapy is feasible, and patients should be carefully evaluated by a multidisciplinary team prior to initial therapy for close monitoring and assessment of the risk–benefit ratio. Therefore, prospective trials are essential to guide clinicians in the decision‐making process. PROSPERO Registration: CRD42022372222.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
踏实奇异果完成签到,获得积分10
1秒前
1秒前
1秒前
木南楠a发布了新的文献求助10
1秒前
得一完成签到,获得积分10
1秒前
2秒前
2秒前
2秒前
3秒前
打打应助CQ采纳,获得10
4秒前
情怀应助11采纳,获得10
4秒前
4秒前
田様应助Young采纳,获得10
6秒前
西野发布了新的文献求助30
6秒前
7秒前
秋不落棠发布了新的文献求助10
7秒前
7秒前
7秒前
灰灰发布了新的文献求助10
8秒前
林林完成签到,获得积分20
8秒前
9秒前
量子星尘发布了新的文献求助200
10秒前
10秒前
海海发布了新的文献求助10
10秒前
10秒前
独特冰安发布了新的文献求助10
10秒前
kai完成签到,获得积分10
10秒前
张思涵完成签到,获得积分10
11秒前
SciGPT应助simon采纳,获得10
12秒前
赫连烙发布了新的文献求助10
13秒前
13秒前
13秒前
lalala发布了新的文献求助10
13秒前
wanci应助ff采纳,获得10
13秒前
柱子完成签到,获得积分10
14秒前
佳析陈关注了科研通微信公众号
15秒前
15秒前
15秒前
16秒前
16秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970843
求助须知:如何正确求助?哪些是违规求助? 3515550
关于积分的说明 11178897
捐赠科研通 3250660
什么是DOI,文献DOI怎么找? 1795393
邀请新用户注册赠送积分活动 875828
科研通“疑难数据库(出版商)”最低求助积分说明 805188